Astrocytes play numerous vital functions in brain development and physiology1. Beside their role at the blood-brain barrier where they regulate nutrient uptake and blood flow, they actively contribute to synapse formation and function while producing neuromodulators that can alter neuronal activity and behavior2. Furthermore, astrocyte dysfunction contributes to a variety of neurological disorders3. Astrocytes located in the cerebral cortex display an elaborate morphology enabling extensive contact with neuronal processes. These contacts, essential for circuit function, also control astrocyte morphogenesis and synaptogenesis through cell-adhesion proteins4. Neuroscientists need convenient and robust tools to investigate astrocyte development and morphogenesis in their neurological models of interest. However, due to the close apposition of astrocytes to their neighbors and their uniform three-dimensional tiling, it is challenging to single out cortical astrocytes and comprehensively assess their morphology using immunomarkers.
Currently, two main genetic engineering strategies enable labeling and individualization of cortical astrocytes in situ: sparse reporter activation in transgenic mouse lines or somatic transgenesis using electroporation of reporter plasmids. The first strategy relies on breeding a floxed reporter mouse line with mice expressing an inducible form of Cre recombinase activated specifically in astrocytes upon tamoxifen delivery (e.g., Aldh1l1-CreERT25). Several disadvantages are associated with this strategy. First, breeding transgenic mice requires a large number of animals and multiple assays are typically needed to determine the proper dose of tamoxifen to provide adequately sparse labeling of cortical astrocytes. Analyzing cortical astrocyte phenotypes in a genetic mouse model of interest will require even more breeding and mouse consumption. Furthermore, in utero tamoxifen injection is known to interfere with parturition, making this strategy difficult to apply to the study of the earliest stages of astrocyte development. In vivo DNA electroporation is an alternative tamoxifen-free strategy that relies on a minimum number of animals6. Performed either at embryonic or postnatal stages, this approach consists of injecting reporter plasmids in the lateral ventricles of rodents followed by electric pulses that create pores in the cell membrane, hence allowing DNA to enter progenitor cells lining the ventricle. Subsequently, the reporter transgenes carried by the electroporated plasmids are processed by the targeted cell machinery and expressed7. Two electroporation methods have been previously described to label mouse cortical astrocytes: 1) Postnatal Astrocyte Labeling by Electroporation (PALE), which relies on the electroporation of 1–2 single-color episomal reporter plasmids at early postnatal stages4; 2) The StarTrack strategy based on in utero electroporation (IUE) of multiple single-color integrative reporter plasmids8,9,10. Although these two techniques efficiently label PrA in the cerebral cortex, they also present some limitations. In their initial version, both methods rely on a glial fibrillary acidic protein (GFAP) promoter to drive expression in astrocytes, which may bias the labelling toward radial glia as well as pial and reactive astrocytes that express GFAP more strongly than normal resting PrA11,12. Regarding PALE, other disadvantages are the late stage of electroporation, which prevents labeling of early-born PrA (or those originating from early delaminating progenitors) and analysis of early stages of astroglia development, and the use of episomal vectors that become diluted through successive divisions during the massive proliferation that PrA undergo during the first postnatal week13,14. In contrast to PALE, StarTrack is based on the embryonic electroporation of integrative reporter plasmids that allow tracking the contribution of both embryonic and postnatal progenitors to PrA. An updated StarTrack scheme relying on the ubiquitin C promoter (UbC-StarTrack) achieves broader expression of fluorescent reporters in both the neuronal and glial descent (astrocytes included) of neural progenitors15,16,17. However, in its current version, implementation of this approach is complex, as it relies on an equimolar mixture of 12 distinct plasmids expressing six fluorescent proteins (FP) with partial excitation and emission spectra overlap.
Presented here is a straightforward in utero electroporation-based multicolor labeling method using integrative reporter constructs driven by a strong and broadly active promoter to single out cortical astrocytes14. In addition, an easy image analysis pipeline using both licensed (e.g., Imaris) and open access (Vaa3D18,19,20) image analysis software is provided to segment astrocyte territorial volume and arborization, respectively. Compared to the previously described methods, this strategy relies solely on 1–2 multicolor integrative transgenes Multiaddressable Genome-Integrating Color Markers (MAGIC Markers or MM21) directed to the cytoplasmic and (optionally) nuclear cell compartment whose expression is driven by a synthetic CAG promoter comprised of a cytomegalovirus enhancer, chicken β-actin promoter, and rabbit β-globin splice acceptor site22. This enables labeling and tracking of cortical astrocytes, from embryonic to late postnatal stages, independent of GFAP expression14,23. Each of these transgenes bears the following four distinct FP: eBFP, mTurquoise2/mCerulean, EYFP, and tdTomato/mCherry, which display minimal spectral overlap that can be easily circumvented with 1) Sequential channel acquisition; 2) Optimized excitation power and collection gain; and 3) Specific dichroic filters to collect narrow FP emission windows. The MM strategy uses Cre/lox recombination with a self-excisable Cre recombinase (seCre) to drive stochastic expression of FP in a cellular population. A single copy of MM transgene expresses FP in a mutually exclusive manner, while multiple transgenes give rise to FP combinations, creating dozens of distinct hues. Genomic integration of the transgenes is driven by the piggyBac (PB) or Tol2 transposition system24,25,26. Therefore, through in utero electroporation, the MM toolkit and the multicolor ‘mosaic’ that it generates enable simultaneous marking of multiple adjacent cortical progenitors and the tracking of their glial descent, including cortical astrocytes, over long periods. Color contrasts resulting from the expression of distinct FP permit delineation of the contour of PrA and subsequently extract key information about their territorial volume (using IMARIS) and complex morphology (using Vaa3D). The multicolor strategy presented in detail here is a convenient and robust method that gives quick and easy access to the cortical astrocyte surface and morphology in wild type mice at various developmental stages, and is easily adaptable to investigate astrocyte anatomical features in mouse models of neurological diseases without using transgenic reporter lines.